TRIGR Therapeutics is a privately-owned company based in Irvine, California focused on the development and commercialization of novel therapeutics for unmet medical needs.
TRIGR is building an asset portfolio of clinical stage and pre-clinical antibodies that will represent the next wave in cancer immunotherapy. We currently have partnered with innovative R&D companies, such as ABL Bio in South Korea, and will develop selected ABL programs into approved immunotherapies worldwide. TRIGR’s diversified pipeline currently consists of immunotherapies against novel and validated targets that have the potential to overcome and modulate biological barriers (e.g. tumor micro-environment) to result in successful treatment outcomes. George Uy, TRIGR founder and CEO: “It is TRIGR’s mission to identify and develop novel and paradigm-shifting immunotherapies addressing unmet medical needs and providing new treatment options to patients and their caregivers. Our immunotherapies are designed to TRIGR the patients’ immune system on our joint conquest to combating and defeating cancer.”
TRIGR strives to be a global pharmaceutical company while maintaining a focus on the Pacific Rim region for clinical and commercial development. We are in the process of assembling a world-class management team of industry veterans that is based in the US and China/Hong Kong and will execute on the efficient development of our immunotherapy programs.